Loading clinical trials...
Loading clinical trials...
A Phase IIb Study to Assess the Safety, Efficacy and Immunogenicity of the Leishmania Vaccine ChAd63-KH in Post-kala Azar Dermal Leishmaniasis
Conditions
Interventions
ChAd63-KH
Placebo
Locations
1
Sudan
Institute of Tropical Medicine
Doka, Gedarif, Sudan
Start Date
April 6, 2020
Primary Completion Date
August 31, 2022
Completion Date
February 28, 2023
Last Updated
May 26, 2023
NCT06917040
NCT06822478
NCT06695143
NCT04888130
NCT04841239
NCT01641796
Lead Sponsor
University of York
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions